Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid derivative class, structurally related to ibuprofen, ketoprofen, and naproxen. It was developed by Janssen Pharmaceutica and marketed primarily as a 1% ophthalmic solution under the brand name Profenal. Suprofen acts as an analgesic, antipyretic, and anti-inflammatory agent. Its primary mechanism of action is inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), leading to reduced synthesis of prostaglandins from arachidonic acid and thus decreasing inflammation and pain. Clinically, it was used to prevent intraoperative miosis during ocular surgery but has been discontinued in the United States due to safety concerns regarding renal effects when used systemically[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on suprofen.